Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sharmila Dorbala, M.D.

Co-Author

This page shows the publications co-authored by Sharmila Dorbala and Ron Blankstein.
Connection Strength

6.788
  1. Adding calcium scoring to myocardial perfusion imaging: Does it alter physicians' therapeutic decision making? J Nucl Cardiol. 2010 Apr; 17(2):168-71.
    View in: PubMed
    Score: 0.433
  2. A Policy Statement on Cardiovascular Test Substitution and Authorization: Principles of Patient-Centered Noninvasive Testing. J Am Coll Cardiol. 2021 09 28; 78(13):1385-1389.
    View in: PubMed
    Score: 0.240
  3. Inter-observer reproducibility and intra-observer repeatability in 99mTc-pyrophosphate scan interpretation for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2022 Apr; 29(2):440-446.
    View in: PubMed
    Score: 0.223
  4. Absolute Quantitation of Cardiac 99mTc-Pyrophosphate Using Cadmium-Zinc-Telluride-Based SPECT/CT. J Nucl Med. 2021 05 10; 62(5):716-722.
    View in: PubMed
    Score: 0.223
  5. Reducing radiation dose from myocardial perfusion imaging in subjects with complex congenital heart disease. J Nucl Cardiol. 2021 08; 28(4):1395-1408.
    View in: PubMed
    Score: 0.207
  6. Stress Myocardial Perfusion PET Provides Incremental Risk Prediction in Patients with and Patients without Diabetes. Radiol Cardiothorac Imaging. 2019 Jun; 1(2):e180018.
    View in: PubMed
    Score: 0.205
  7. Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. Radiology. 2019 05; 291(2):330-337.
    View in: PubMed
    Score: 0.201
  8. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. J Am Heart Assoc. 2019 01 08; 8(1):e007829.
    View in: PubMed
    Score: 0.199
  9. Erratum to: Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol. 2018 Aug; 25(4):1147.
    View in: PubMed
    Score: 0.193
  10. Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2018 01; 11(1):e007030.
    View in: PubMed
    Score: 0.185
  11. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017 10; 24(5):1741-1758.
    View in: PubMed
    Score: 0.182
  12. Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol. 2018 08; 25(4):1136-1146.
    View in: PubMed
    Score: 0.169
  13. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol. 2017 02; 24(1):86-99.
    View in: PubMed
    Score: 0.166
  14. Prognostic value of coronary CTA vs. exercise treadmill testing: results from the Partners registry. Eur Heart J Cardiovasc Imaging. 2015 Dec; 16(12):1338-46.
    View in: PubMed
    Score: 0.154
  15. Approaches to reducing radiation dose from radionuclide myocardial perfusion imaging. J Nucl Med. 2015 Apr; 56(4):592-9.
    View in: PubMed
    Score: 0.153
  16. Reply: (18)F-FDG imaging in patients with "suspected," but not "proven," sarcoidosis. J Am Coll Cardiol. 2014 Aug 12; 64(6):631.
    View in: PubMed
    Score: 0.147
  17. Comparison of the use of downstream tests after exercise treadmill testing by cardiologists versus noncardiologists. Am J Cardiol. 2014 Jul 15; 114(2):305-11.
    View in: PubMed
    Score: 0.144
  18. Reply: Cardiac positron emission tomography as a prognostic indicator of cardiac sarcoidosis. J Am Coll Cardiol. 2014 Jun 17; 63(23):2590.
    View in: PubMed
    Score: 0.143
  19. Yield of downstream tests after exercise treadmill testing: a prospective cohort study. J Am Coll Cardiol. 2014 Apr 08; 63(13):1264-1274.
    View in: PubMed
    Score: 0.141
  20. Reduction in ¹8F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014 Feb; 21(1):166-74.
    View in: PubMed
    Score: 0.140
  21. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014 Feb 04; 63(4):329-36.
    View in: PubMed
    Score: 0.138
  22. Detection of obstructive coronary artery disease using regadenoson stress and 82Rb PET/CT myocardial perfusion imaging. J Nucl Med. 2013 Oct; 54(10):1748-54.
    View in: PubMed
    Score: 0.137
  23. Use of multimodality imaging to diagnose cardiac sarcoidosis as well as identify recurrence following heart transplantation. J Nucl Cardiol. 2013 Apr; 20(2):310-2.
    View in: PubMed
    Score: 0.133
  24. Use of high-risk features from exercise treadmill testing to identify obstructive left main disease with normal myocardial perfusion imaging. J Nucl Cardiol. 2012 Aug; 19(4):814-7.
    View in: PubMed
    Score: 0.127
  25. Correlative imaging of spontaneous coronary artery dissection. J Nucl Cardiol. 2012 Jun; 19(3):625-9.
    View in: PubMed
    Score: 0.126
  26. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. J Nucl Cardiol. 2012 Oct; 19(5):970-8.
    View in: PubMed
    Score: 0.125
  27. Cardiomyopathy of uncertain etiology: Complementary role of multimodality imaging with cardiac MRI and 18FDG PET. J Nucl Cardiol. 2010 Apr; 17(2):328-32.
    View in: PubMed
    Score: 0.108
  28. Association of Myocardial Blood Flow Reserve With Adverse Left Ventricular Remodeling in Patients With Aortic Stenosis: The Microvascular Disease in Aortic Stenosis (MIDAS) Study. JAMA Cardiol. 2022 01 01; 7(1):93-99.
    View in: PubMed
    Score: 0.061
  29. Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer. J Nucl Cardiol. 2021 Nov 24.
    View in: PubMed
    Score: 0.061
  30. Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease. Eur Heart J. 2021 Sep 07.
    View in: PubMed
    Score: 0.060
  31. Role of Exercise Treadmill Testing in the Assessment of Coronary Microvascular Disease. JACC Cardiovasc Imaging. 2022 02; 15(2):312-321.
    View in: PubMed
    Score: 0.060
  32. Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus. J Am Heart Assoc. 2021 07 06; 10(13):e018555.
    View in: PubMed
    Score: 0.059
  33. Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World. JACC Cardiovasc Imaging. 2021 09; 14(9):1787-1799.
    View in: PubMed
    Score: 0.059
  34. Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. JACC Cardiovasc Imaging. 2021 11; 14(11):2212-2220.
    View in: PubMed
    Score: 0.058
  35. Cardiopulmonary transit time: A novel PET imaging biomarker of in vivo physiology for risk stratification of heart transplant recipients. J Nucl Cardiol. 2021 Jan 04.
    View in: PubMed
    Score: 0.057
  36. Cardiac Imaging in the Post-ISCHEMIA Trial Era: A Multisociety Viewpoint. JACC Cardiovasc Imaging. 2020 08; 13(8):1815-1833.
    View in: PubMed
    Score: 0.055
  37. Coronary vasomotor dysfunction in cancer survivors treated with thoracic irradiation. J Nucl Cardiol. 2021 12; 28(6):2976-2987.
    View in: PubMed
    Score: 0.055
  38. Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure. Eur Heart J. 2020 07 01; 41(25):2366-2375.
    View in: PubMed
    Score: 0.055
  39. Coronary microvascular dysfunction in patients with psoriasis. J Nucl Cardiol. 2022 Feb; 29(1):37-42.
    View in: PubMed
    Score: 0.055
  40. Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. J Am Coll Cardiol. 2020 06 30; 75(25):3177-3183.
    View in: PubMed
    Score: 0.055
  41. Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. Ann Thorac Surg. 2020 08; 110(2):733-740.
    View in: PubMed
    Score: 0.055
  42. Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. Can J Cardiol. 2020 07; 36(7):971-976.
    View in: PubMed
    Score: 0.055
  43. Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. Circulation. 2020 01 07; 141(1):21-33.
    View in: PubMed
    Score: 0.053
  44. Appropriateness of inpatient stress testing: Implications for development of clinical decision support mechanisms and future criteria. J Nucl Cardiol. 2021 10; 28(5):1988-1997.
    View in: PubMed
    Score: 0.053
  45. Feasibility of somatostatin receptor-targeted imaging for detection of myocardial inflammation: A pilot study. J Nucl Cardiol. 2021 06; 28(3):1089-1099.
    View in: PubMed
    Score: 0.051
  46. Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2019 06; 12(6):e008975.
    View in: PubMed
    Score: 0.051
  47. Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in aortic stenosis. J Nucl Cardiol. 2021 Apr; 28(2):579-588.
    View in: PubMed
    Score: 0.051
  48. Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients. J Am Coll Cardiol. 2018 08 14; 72(7):707-717.
    View in: PubMed
    Score: 0.048
  49. Myocardial Scar But Not Ischemia Is Associated With Defibrillator Shocks and Sudden Cardiac Death in Stable Patients With Reduced Left Ventricular Ejection Fraction. JACC Clin Electrophysiol. 2018 09; 4(9):1200-1210.
    View in: PubMed
    Score: 0.048
  50. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018 03 07; 39(10):840-849.
    View in: PubMed
    Score: 0.047
  51. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol. 2018 Feb; 25(1):298-319.
    View in: PubMed
    Score: 0.047
  52. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy. Eur Heart J. 2018 01 21; 39(4):316-323.
    View in: PubMed
    Score: 0.047
  53. Coronary Microvascular Dysfunction Identifies Patients at High Risk of Adverse Events Across Cardiometabolic Diseases. J Am Coll Cardiol. 2017 12 05; 70(22):2835-2837.
    View in: PubMed
    Score: 0.046
  54. Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. Kidney Int. 2018 02; 93(2):501-509.
    View in: PubMed
    Score: 0.046
  55. Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease. Circulation. 2017 Dec 12; 136(24):2325-2336.
    View in: PubMed
    Score: 0.045
  56. Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med. 2017 08; 58(8):1341-1353.
    View in: PubMed
    Score: 0.045
  57. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. J Am Heart Assoc. 2017 May 04; 6(5).
    View in: PubMed
    Score: 0.044
  58. Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease. Circulation. 2017 02 07; 135(6):566-577.
    View in: PubMed
    Score: 0.043
  59. Prognostic Value of Coronary Flow Reserve in Patients with Dialysis-Dependent ESRD. J Am Soc Nephrol. 2016 06; 27(6):1823-9.
    View in: PubMed
    Score: 0.040
  60. Response to letter regarding article, "effects of sex on coronary microvascular dysfunction and cardiac outcomes". Circulation. 2015 Mar 17; 131(11):e376.
    View in: PubMed
    Score: 0.038
  61. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging. 2015 Aug; 16(8):900-9.
    View in: PubMed
    Score: 0.038
  62. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. Circulation. 2015 Feb 10; 131(6):528-35.
    View in: PubMed
    Score: 0.037
  63. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015 Jan 06; 131(1):19-27.
    View in: PubMed
    Score: 0.037
  64. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014 Jun 17; 129(24):2518-27.
    View in: PubMed
    Score: 0.036
  65. Preserved coronary flow reserve effectively excludes high-risk coronary artery disease on angiography. J Nucl Med. 2014 Feb; 55(2):248-55.
    View in: PubMed
    Score: 0.035
  66. Prognostic interplay of coronary artery calcification and underlying vascular dysfunction in patients with suspected coronary artery disease. J Am Coll Cardiol. 2013 May 21; 61(20):2098-106.
    View in: PubMed
    Score: 0.033
  67. Coronary vascular dysfunction and prognosis in patients with chronic kidney disease. JACC Cardiovasc Imaging. 2012 Oct; 5(10):1025-34.
    View in: PubMed
    Score: 0.032
  68. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012 Oct 09; 126(15):1858-68.
    View in: PubMed
    Score: 0.032
  69. Quantitative relationship between the extent and morphology of coronary atherosclerotic plaque and downstream myocardial perfusion. J Am Coll Cardiol. 2011 Oct 18; 58(17):1807-16.
    View in: PubMed
    Score: 0.030
  70. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011 Nov 15; 124(20):2215-24.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.